



September 11, 2023

RE: ADHD Medications, Xyrem[®], Risperdal Consta[®], and Tirosint[®] capsules Coverage Changes Effective September 25, 2023

The following changes will take effect September 25, 2023. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy PA forms can be found on the OHCA website at <https://oklahoma.gov/ohca/rxforms>.

ADHD Medications

Select changes to the ADHD Medications Tier chart include the following:

- Relexxii[®] and generic methylphenidate extended-release (ER) 72mg tablets will be moved to the Special PA Tier.
- Ritalin LA[®] will be moved to Tier-2.
- Aptensio XR[™] and Daytrana[®] will be brand preferred.

The specific PA requirements and full Tier chart for the ADHD Medications can be found in the “Central Nervous System/Behavioral Health” therapeutic category.

***Reminder: Generic lisdexamfetamine is now available; however, Vyvanse[®] capsules and chewable tablets are brand preferred.**

Xyrem[®]

Xyrem[®] (sodium oxybate) will be brand preferred. Brand Xyrem[®] will continue to require a PA. The PA requirements can be found in the “Central Nervous System/Behavioral Health” therapeutic category.

Risperdal Consta[®]

Risperdal Consta[®] (risperidone ER injection) will be moved to Tier-3. Current utilizers will be approved for continuation of therapy. For members new to therapy, authorization will require a patient-specific, clinically significant reason why one of the lower-tiered long-acting injectables for the requested medication cannot be used, which are available without PA. The specific PA requirements and Tier chart for the Atypical Antipsychotic Medications can be found in the “Central Nervous System/Behavioral Health” therapeutic category.

Tirosint[®] Capsules

Tirosint[®] (levothyroxine) capsules will be brand preferred. Members wanting to continue therapy on generic levothyroxine capsules will need to submit a PA request. Brand Tirosint[®] capsules will continue to require a PA. The specific PA requirements can be found in the “Special Formulation” therapeutic category.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS



ADDRESS

4345 N. Lincoln Blvd.
Oklahoma City, OK 73105



WEBSITES

oklahoma.gov/ohca
mysoonerCare.org



PHONE

Admin: 405-522-7300
Helpline: 800-987-7767